ELI LILLY & CO (LLY)

US5324571083 - Common Stock

726.31  -19.64 (-2.63%)

Premarket: 729.88 +3.57 (+0.49%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ELI LILLY & CO

NYSE:LLY (4/19/2024, 7:04:00 PM)

Premarket: 729.88 +3.57 (+0.49%)

726.31

-19.64 (-2.63%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap690.55B
Shares
PE114.92
Fwd PE57.69
Dividend Yield0.7%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LLY Daily chart

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 39,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. The firm's subsidiary is POINT Biopharma Global Inc., which is a radiopharmaceutical company with a pipeline of clinical and preclinical stage radioligand therapies in development for the treatment of cancer. The firm's products are sold in over 110 countries.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr

Indianapolis INDIANA 46285

P: 13172762000

CEO: David A. Ricks

Employees: 39000

Website: https://www.lilly.com/

LLY News

News Image2 hours ago - BloombergTikTok’s Crackdown on Ozempic Influencers Threatens Weight-Loss Drug Hype Machine

Creators say the rules are unfair and harmful to their businesses

News Image3 hours ago - TheNewswire.com6 Stocks Positioned to Soar as Investors Focus on MASH

Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was expanded to treat obesity, an even bigger market. JP Morgan analyst Richard Vosser estimated the global obesity drug market will reach $71 billion by 2032.

News Image7 hours ago - BloombergAfrica’s Biggest Drugmaker Can Help Ease Obesity Medicine Supply Crunch

Africa’s biggest drugmaker could potentially help ease a growing supply crunch for the world’s hottest obesity medications.

News Image2 days ago - The Motley FoolMissed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

News Image2 days ago - CNBCMost people on weight loss drugs are spending less on restaurants and takeout, survey says

The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.

News Image2 days ago - The Motley Fool3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

LLY Twits

Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example